Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma
Journal for ImmunoTherapy of Cancer · 2026-10 · 14 (10) · e015489
DOI: 10.1136/jitc-2026-015489 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 29.10.2026. Verfasst von Alexander K Tsai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, American Cancer Society.
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with limited therapeutic options. Adoptive cell therapy (ACT) using tumor-reactive T cell receptor-engineered T cells (TCR-T) is a promising therapeutic modality for targeting PDA. However, additional strategies are needed to overcome the suppressive tumor microenvironment (TME) that impairs T cell persistence and function. Tumor growth factor-β (TGFβ) is a prominent immunosuppressive component of the TME, but is also believed to be critical for T cell memory.
Methods
We develop aggressive immunocompetent orthotopic KrasLSL-G12D/+;Trp53LSL-R172H/+;p48-Cre (KPC) PDA mouse models to identify obstacles to sustained activity of TCR-T cell therapy targeting the native tumor antigen, mesothelin (Msln). During ACT, we track TCR-T cell fate, function, antitumor effects, and interactions with type I dendritic cells using flow cytometry, two-photon microscopy, and live-cell imaging. Based on an abundance of TGFβ and a halt in TCR-T cell differentiation in orthotopic tumors, TCR-T cells with defective Tgfbr2 are tested in a new model, where peptide-major histocompatibility complex-I (pMHC-I) is incrementally augmented on KPC tumor cells.
Results
TCR-T cells accumulated in orthotopic PDA but were rendered dysfunctional despite lacking features of exhaustion. KPC tumor cells express minimal constitutive MHC-I, resulting in suboptimal recognition by TCR-T cells. Modestly increasing pMHC-I on KPC tumor cells restored canonical differentiation of TCR-T cells into PD-1+ progenitor exhausted (TPEX) in PDA, but failed to rescue interferon-γ (IFNγ) production. TGFβ was enriched in tumor nests, and deletion of Tgfbr2 in TCR-T cells enhanced dendritic cell interactions, reduced intratumoral TGFβ deposition, restored IFNγ production, and improved therapeutic efficacy without compromising TCR-T cell longevity or tissue residency.
Conclusions
Modestly enhancing tumor-intrinsic pMHC-I unleashes therapeutic efficacy and functionality of Tgfbr2-disrupted TCR-T cells in PDA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
- Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
- Program in Immunology and Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
- Center for Multiparametric Imaging of Tumor Immune Microenvironments, University of Minnesota, Minneapolis, Minnesota, USA.
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- American Cancer Society
- American Association for Cancer Research
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- Congressionally Directed Medical Research Programs
- Masonic Cancer Center, University of Minnesota
Zitieren
APA
Tsai, A. K., Rollins, M. R., Ellefson, M. A., Schmiechen, Z. C., Burrack, A. L., Hulbert, A., Qian, G., Zhang, H., Cruz-Hinojoza, E., Butler, J. Z., Mitchell, J. S., Ghirardelli Smith, O. C., O'Flanagan, S. D., Krause, J., Hickok, G. H., Provenzano, P. P., Masopust, D., Hingorani, S. R., Greenberg, P. D., & Stromnes, I. M. (2026). Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Journal for ImmunoTherapy of Cancer, 14(10), e015489. https://doi.org/10.1136/jitc-2026-015489
Vancouver
Tsai AK, Rollins MR, Ellefson MA, Schmiechen ZC, Burrack AL, Hulbert A, et al. Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Journal for ImmunoTherapy of Cancer. 2026;14(10):e015489. doi:10.1136/jitc-2026-015489
BibTeX
@article{Tsai2026,
author = {Tsai, Alexander K and Rollins, Meagan R and Ellefson, Madeline A and Schmiechen, Zoe C and Burrack, Adam L and Hulbert, Ayaka and Qian, Guhan and Zhang, Hongrong and Cruz-Hinojoza, Eduardo and Butler, Jonah Z and Mitchell, Jason S and Ghirardelli Smith, Olivia C and O'Flanagan, Stephen D and Krause, Jenny and Hickok, Grant H and Provenzano, Paolo P and Masopust, David and Hingorani, Sunil R and Greenberg, Philip D and Stromnes, Ingunn M},
title = {Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {10},
pages = {e015489},
doi = {10.1136/jitc-2026-015489}
}
EUVIMED